AI Festa 2025

스탠다임

기업 홈페이지 바로가기

[기업소개]: Standigm harnesses the power of AI to pioneer drug discovery, developing both proprietary and collaborative research pipelines. Our AI platform approach includes a biology platform for uncovering novel drug targets and a chemistry platform for designing molecules to modulate these targets effectively. In addition to pipeline development, we also offer AI platform services, empowering partners across the globe to accelerate their drug discovery processes and achieve groundbreaking advancements in medicine.

[주요 제품]: Standigm has developed AI platforms to accelerate drug discovery by optimizing target identification, molecular design, and compound evaluation. Standigm ASK™ and Standigm BEST™ integrate AI models, database, and predictive analytics to streamline early-stage drug discovery.

Standigm ASK™ focuses on AI-driven drug target identification, integrating knowledge-based and omics-based technologies.

Key Features:
ASK-Pathfinder™ predicts target-disease associations using a biomedical knowledge graph.
ASK-SCREENER™ extracts disease-target relationships from text.
ASK-PWN™ identifies disease-specific targets by applying omics data to a modified PPI network.
ASK-GSM™ identifies metabolism-related targets using patient- or disease-specific metabolic models based on transcriptomic data.

Standigm BEST™ accelerates hit-to-lead and lead-to-preclinical candidate selection with AI-powered drug design and optimization, combining generative AI, predictive modeling, and automation to streamline drug design and optimization, combining generative AI, predictive modeling, and automation to streamline drug discovery process.

Key Features:

BEST-STELLA™ generates molecules with desired multi-pharmaceutical properties.
BEST-SPICA™ provides a rapid novelty assessment for compouns.
BEST-QIP-ADMET™ predicts ADMET properties using Quantum-Informed pretrained model.
BEST-GT-QSAR™ automates SAR modeling and AI optimization.

목록으로

전시참가업체